

Sofia R Gameiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3541132/publications.pdf>

Version: 2024-02-01

43
papers

3,209
citations

236925

25
h-index

345221

36
g-index

44
all docs

44
docs citations

44
times ranked

4765
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
2	Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget, 2014, 5, 403-416.	1.8	331
3	Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer, 2013, 133, 624-636.	5.1	225
4	Dual targeting of TGF- β 2 and PD-L1 via a bifunctional anti-PD-L1/TGF- β 2RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
5	M7824, a novel bifunctional anti-PD-L1/TGF- β 2 Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. OncoImmunology, 2018, 7, e1426519.	4.6	162
6	The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors. Seminars in Oncology, 2012, 39, 323-339.	2.2	132
7	If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer, 2019, 5, 37.	5.2	132
8	Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. International Journal of Radiation Oncology Biology Physics, 2016, 95, 120-130.	0.8	117
9	Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 12-22.	1.0	101
10	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget, 2016, 7, 7390-7402.	1.8	89
11	Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. , 2019, 7, 82.		76
12	Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 153-161.	1.0	71
13	Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunology, Immunotherapy, 2011, 60, 1227-1242.	4.2	66
14	Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget, 2014, 5, 9335-9348.	1.8	64
15	Sublethal exposure to alpha radiation (^{223}Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget, 2016, 7, 86937-86947.	1.8	63
16	Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression. PLoS ONE, 2013, 8, e70417.	2.5	57
17	Immunotherapy utilizing the combination of natural killer and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. , 2018, 6, 133.		56
18	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. Npj Breast Cancer, 2019, 5, 34.	5.2	55

#	ARTICLE	IF	CITATIONS
19	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. <i>Oncolimmunology</i> , 2018, 7, e1466018.	4.6	51
20	Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF- β 2 signaling enables PD-L1-mediated tumor eradication. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	50
21	Rationale for IL-15 superagonists in cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 705-709.	3.1	46
22	Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. <i>Oncolimmunology</i> , 2014, 3, e28643.	4.6	44
23	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. , 2018, 6, 59.		43
24	Defining Molecular Signature of Pro-Immunogenic Radiotherapy Targets in Human Prostate Cancer Cells. <i>Radiation Research</i> , 2014, 182, 139-148.	1.5	41
25	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. <i>Nature Communications</i> , 2021, 12, 5151.	12.8	41
26	Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 23-35.	1.0	36
27	Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process. <i>Cancer Research</i> , 2014, 74, 1945-1957.	0.9	31
28	Combination Regimens of Radiation Therapy and Therapeutic Cancer Vaccines: Mechanisms and Opportunities. <i>Seminars in Radiation Oncology</i> , 2015, 25, 46-53.	2.2	30
29	The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. <i>Oncolimmunology</i> , 2019, 8, e1532764.	4.6	30
30	Attacking malignant cells that survive therapy. <i>Oncolimmunology</i> , 2013, 2, e26937.	4.6	29
31	Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. , 2020, 8, e000493.		27
32	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 704-716.	7.0	26
33	Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin. <i>Oncotarget</i> , 2016, 7, 23498-23511.	1.8	25
34	Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1359-1370.	3.4	22
35	Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. <i>Expert Review of Vaccines</i> , 2013, 12, 617-629.	4.4	18
36	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581801.	2.8	11

#	ARTICLE	IF	CITATIONS
37	Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer. Clinical and Translational Science, 2010, 3, 116-122.	3.1	9
38	Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGF β 2RII agent: Current status. Experimental Biology and Medicine, 2022, 247, 1124-1134.	2.4	7
39	Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy. Oncoimmunology, 2015, 4, e1009303.	4.6	5
40	Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. Oncoimmunology, 2021, 10, 1915561.	4.6	5
41	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. JCI Insight, 2022, 7, .	5.0	5
42	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS5096-TPS5096.	1.6	3
43	Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. , 2014, , .		1